Insider · CIK 0002131341
Anthony W. Opipari
Files at ODTX (Odyssey Therapeutics, Inc.). First filing -, latest -.
In brief
Anthony W. Opipari files SEC Form 4 as officer at ODTX (Odyssey Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Anthony W. Opipari has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | CConversion Common Stock | +6,965 | - | - | 6,965 | May 11, 2026 |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | MOption exercise Common Stock | +541 | - | - | 7,506 | May 11, 2026 |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | FTax withholding Common Stock | -4 | $18.00 | $72 | 7,502 | May 11, 2026 |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | CConversion Series A Convertible Preferred Stockderivative | -18,531 | - | - | 0 | May 11, 2026 |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | CConversion Series B Convertible Preferred Stockderivative | -11,083 | - | - | 0 | May 11, 2026 |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | CConversion Series C Convertible Preferred Stockderivative | -20,000 | - | - | 0 | May 11, 2026 |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | CConversion Series D Convertible Preferred Stockderivative | -17,545 | - | - | 0 | May 11, 2026 |
| May 7, 2026 | ODTX Odyssey Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +250,203 | $0.00 | $0 | 250,203 | May 11, 2026 |
| May 7, 2026 | ODTX Odyssey Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +27,777 | $0.00 | $0 | 27,777 | May 11, 2026 |
| May 11, 2026 | ODTX Odyssey Therapeutics, Inc. | MOption exercise Series D Warrants (Right to Buy)derivative | -5,263 | - | - | 0 | May 11, 2026 |
Questions about Anthony W. Opipari
Answered from the filings on this page, as of the latest one.
Is Anthony W. Opipari buying or selling?
Anthony W. Opipari has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Anthony W. Opipari's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Anthony W. Opipari has 0.
Where does Anthony W. Opipari file Form 4?
Anthony W. Opipari has filed Form 4 at ODTX (Odyssey Therapeutics, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.